logo

For the Inventor, By the Inventor

Newark, DE, United States of America

Yong Li

This inventor holds 5 USPTO granted patents and 13 published patent applications. Top assignee: Incyte Corporation. Active years: 2021-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yong Li. Retrieved from https://idiyas.com/inventor/yong-li-6myg533n

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 

% Patents Active = 80.0

Average Co-Inventor Count = 8.5

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:

goldMedal5 out of 687 
 
Incyte Corporation
 patents

Years Active: 2021-2026

Loading Chart...
5 patents (USPTO):Explore Patents
1. 12735424 - Fused pyrazine derivatives as A2A / A2B inhibitors (2026-09-15),
2. 12441727 - Tricyclic compounds as inhibitors of KRAS (2025-10-14),
3. 12060433 - CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy (2024-08-13),
4. 11999740 - Fused pyrazine derivatives as A2A / A2B inhibitors (2024-06-04),
5. 11161850 - Fused pyrazine derivatives as A2A / A2B inhibitors (2021-11-02),

Title: The Innovative Contributions of Yong Li

Introduction

Yong Li is a prominent inventor based in Newark, DE (US), known for his significant contributions to the field of pharmaceutical sciences. With a total of four patents to his name, he has made remarkable strides in developing therapies that target critical biological pathways.

Latest Patents

Among his latest patents, Yong Li has developed tricyclic compounds as inhibitors of KRAS. These compounds are designed to inhibit KRAS activity, which is crucial in treating diseases associated with this pathway, particularly cancer. Another notable patent involves a combination therapy that includes a CD73 inhibitor and an A2A/A2B adenosine receptor inhibitor. This innovative therapy aims to address various diseases related to adenosine receptor activity, including cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative disorders.

Career Highlights

Yong Li is currently associated with Incyte Corporation, where he continues to advance his research and development efforts. His work has been instrumental in creating new therapeutic options that have the potential to improve patient outcomes in various medical conditions.

Collaborations

Yong Li collaborates with talented colleagues, including Xiaozhao Wang and Wenqing Yao, to further enhance the impact of his research. Their combined expertise contributes to the innovative environment at Incyte Corporation.

Conclusion

Yong Li's contributions to the field of pharmaceuticals through his patents and collaborative efforts highlight his role as a leading inventor. His work not only advances scientific knowledge but also holds promise for improving treatments for serious health conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…